专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09163019B2 Inhibitor compounds of phosphodiesterase type 10A 有权
标题翻译：磷酸二酯酶10A型抑制剂化合物
公开(公告)号：US09163019B2
公开(公告)日：2015-10-20
申请号：US14208067
申请日：2014-03-13
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Hervë Geneste , Michael Ochse , Karla Drescher , Berthold Behl , Loic Laplanche , Jürgen Dinges , Clarissa Jakob
IPC分类号： A61K31/54 , C07D471/02 , C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims.The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
摘要翻译：本发明涉及式I化合物，N-氧化物，互变异构体，前药及其药学上可接受的盐：在式I中，变量Het，A，X，Y，Z，R1，R2，R3，R4， R5和Q如权利要求中所定义。式I化合物，N-氧化物，互变异构体，其前药和药学上可接受的盐是10A型磷酸二酯酶的抑制剂。因此，本发明还涉及式I化合物，N-氧化物，互变异构体，前药和其药学上可接受的盐在制备药物中的用途，因此其适用于治疗或控制医学病症选自神经障碍和精神障碍，用于改善与这种障碍相关的症状并降低这种障碍的风险。

2. 发明授权

US10556914B2 Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use 有权
公开(公告)号：US10556914B2
公开(公告)日：2020-02-11
申请号：US16409323
申请日：2019-05-10
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Jürgen Dinges , Achim Moeller , Michael Ochse , Martin Schmidt , Michael Schulz , Sean Turner , Elizabeth Louise Van Der Kam , Anil Vasudevan
IPC分类号： C07D498/04 , C07D513/04 , A61K31/4985
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

3. 发明授权

US10556907B2 Fused heterocyclic compounds as S1P modulators 有权
公开(公告)号：US10556907B2
公开(公告)日：2020-02-11
申请号：US15248994
申请日：2016-08-26
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Udo Lange , Michael Ochse , Elizabeth van der Kam , Jeroen van Bergeijk , Sean Turner , Frank Oellien , Patrick Walleser , Wilhelm Amberg , Wilfried Hornberger , Herve Geneste , Mario Mezler , Charles Hutchins
IPC分类号： C07D487/04 , C07D471/04
摘要： The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

4. 发明申请

US20180222905A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A 审中-公开
公开(公告)号：US20180222905A1
公开(公告)日：2018-08-09
申请号：US15948299
申请日：2018-04-09
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Hervé Geneste , Michael Ochse , Karla Drescher , Berthold Behl , Loic Laplanche , Jürgen Dinges , Clarissa Jakob , Katja Jantos
IPC分类号： C07D471/04 , C07D413/14 , C07D403/14 , C07D405/14 , C07D409/14
CPC分类号： C07D471/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要： The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

5. 发明授权

US09790203B2 Inhibitor compounds of phosphodiesterase type 10A 有权
公开(公告)号：US09790203B2
公开(公告)日：2017-10-17
申请号：US14087680
申请日：2013-11-22
申请人： ABBVIE DEUTSCHLAND GMBH & CO. KG , ABBVIE INC.
发明人： Hervé Geneste , Sean Colm Turner , Michael Ochse , Karla Drescher , Lawrence A. Black , Katja Jantos
IPC分类号： C07D401/14 , C07D401/04 , C07D401/10 , C07D471/04 , C07D487/04
CPC分类号： C07D401/14 , C07D401/04 , C07D401/10 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

6. 发明申请

US20150158842A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 审中-公开
标题翻译： PHENALKYLAMINE衍生物，含有它们的药物组合物及其在治疗中的使用
公开(公告)号：US20150158842A1
公开(公告)日：2015-06-11
申请号：US14617737
申请日：2015-02-09
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Charles W. Hutchins , Wilfried Hornberger , Mario Mezler
IPC分类号： C07D401/12
CPC分类号： C07D401/12 , A61K31/357 , A61K31/472 , A61K31/4725 , A61K31/538 , C07D217/02 , C07D217/08 , C07D217/22 , C07D217/26
摘要： The present invention relates to phenalkylamine derivatives of the formula (I) or (II) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及式（I）或（II）的苯烷基胺衍生物或其生理上耐受的盐。本发明涉及包含这种苯烷基胺衍生物的药物组合物，以及这种苯烷基胺衍生物用于治疗目的的用途。酚烷基胺衍生物是GlyT1抑制剂。

7. 发明申请

US20170057966A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS 审中-公开
标题翻译：熔融杂环化合物作为S1P调节剂
公开(公告)号：US20170057966A1
公开(公告)日：2017-03-02
申请号：US15248994
申请日：2016-08-26
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Udo Lange , Michael Ochse , Elizabeth van der Kam , Jeroen van Bergeijk , Sean Turner , Frank Oellien , Patrick Walleser , Wilhelm Amberg , Wilfried Hornberger , Herve Geneste , Mario Mezler , Charles Hutchins
IPC分类号： C07D487/04 , C07D471/04
CPC分类号： C07D487/04 , C07D471/04
摘要： The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
摘要翻译：本发明涉及作为S1P调节剂的杂环化合物，包含这些化合物的药物组合物及其用于治疗，缓解或预防由S1P受体介导的疾病或病症的用途。

8. 发明申请

US20160318871A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A 有权
公开(公告)号：US20160318871A1
公开(公告)日：2016-11-03
申请号：US15207137
申请日：2016-07-11
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Hervé Geneste , Michael Ochse , Karla Drescher , Jürgen Dinges , Clarissa Jakob
IPC分类号： C07D217/26 , C07D401/14 , C07D471/04 , C07D401/12 , C07D417/12 , C07D409/12 , C07D401/06 , C07D237/32
CPC分类号： C07D217/26 , A61K31/47 , C07D217/24 , C07D237/32 , C07D401/06 , C07D401/12 , C07D401/14 , C07D409/08 , C07D409/12 , C07D413/06 , C07D417/06 , C07D417/12 , C07D471/04
摘要： The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. wherein X1 is CH or N, X2 is C—R5 or N, Y is O or S, R1 is inter alia C2-C8-alkyl, C2-C8-alkenyl, C1-C4-fluoroalkyl, C3-C8-cycloalkyl, C5-C8-cycloalkyl carrying a fused benzene ring, or a moiety Z1—Ar1; R2 is a radical of the formula CR21R22R23 or phenyl or 5- or 6-membered hetaryl having 1, 2 or 3 heteroatoms as ring members which are selected from O, S and N, where phenyl and monocyclic hetaryl are unsubstituted or may carry 1, 2 or 3 identical or different substituents Ra, R3 is inter alia hydrogen, C1-C8-alkyl, C2-C8-alkenyl, C1-C4-fluoroalkyl, C3-C8-cycloalkyl, etc, or R2 and R3 together with the nitrogen atom, to which they are bound form an optionally substituted saturated 5- to 7-membered heterocyclic ring which, in addition to the nitrogen atom, may have 1 or 2 further heteroatoms or heteroatom containing groups selected from the group of O, N, S, SO and SO2; R4 is inter alia C1-C4-alkyl, C1-C4-fluoroalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl or Z4—Ar4; R5 is inter alia hydrogen, halogen, C1-C4-alkyl, C1-C4-fluoroalkyl, C1-C4-alkoxy, C1-C4-fluoroalkoxy, —Z5—Ar5, —O—Z5—Ar5, etc; where Z1 to Z5, Ar1 to Ar5, Ra, R21, R22, and R23 are as defined in the claims.

9. 发明授权

US09096619B2 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
标题翻译：氨基四氢萘衍生物，含有它们的药物组合物及其在治疗中的应用
公开(公告)号：US09096619B2
公开(公告)日：2015-08-04
申请号：US13789967
申请日：2013-03-08
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC分类号： A61K31/135 , C07C211/27 , A61K31/16 , C07C215/70 , C07F7/08 , C07D295/135 , C07D265/30 , C07D403/12 , C07D207/09 , C07D205/04 , C07D305/08 , C07C271/24 , C07C311/13 , C07C317/28 , C07D213/71 , C07C255/58 , C07D231/18 , C07C307/06 , C07D333/34 , C07C309/65 , C07D233/84 , C07C311/05 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C215/64 , C07C217/74 , C07D249/12 , C07C233/18 , C07C233/19 , C07D261/08 , C07C233/69 , C07D207/10 , C07D207/12 , C07D207/27 , C07D275/02 , C07D207/36 , C07D207/48 , C07D295/096
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及式（I）的氨基四氢化萘衍生物或其生理上耐受的盐。本发明涉及包含这种氨基四氢化萘衍生物的药物组合物，以及这种氨基四氢化萘衍生物用于治疗目的的用途。氨基四氢叶酸衍生物是GlyT1抑制剂。

10. 发明申请

US20130184238A1 AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权
标题翻译：氨基嘌呤衍生物，含有它们的药物组合物及其在治疗中的使用
公开(公告)号：US20130184238A1
公开(公告)日：2013-07-18
申请号：US13789967
申请日：2013-03-08
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC分类号： C07F7/08 , C07D265/30 , C07D403/12 , C07C317/28 , C07D205/04 , C07D305/08 , C07C271/24 , C07C311/13 , C07D295/135 , C07D207/09
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及式（I）的氨基四氢化萘衍生物或其生理上耐受的盐。本发明涉及包含这种氨基四氢化萘衍生物的药物组合物，以及这种氨基四氢化萘衍生物用于治疗目的的用途。氨基四氢叶酸衍生物是GlyT1抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式